Medindia

X

Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT

Tuesday, May 13, 2008 General News J E 4
Advertisement
GAITHERSBURG, Md., May 12 Iomai Corporation(Nasdaq: IOMI) today said that it will host a conference call and live webcasttomorrow to discuss today's announcement that Intercell AG (VSE: ICLL) andIomai have entered into a definitive agreement pursuant to which Intercellwill acquire Iomai for USD 6.60 per share representing a fully diluted equityvalue of approximately USD 189 million (EUR 122 million).

The conference call and webcast will be held at 8:30 a.m. Eastern Timetomorrow, Tuesday, May 13.

Conference Call Details

To access the live conference call Tuesday, May 13, 2008 at 8:30 a.m.Eastern Time via phone, please dial 866-713-8395 from the United States andCanada or 617-597-5309 internationally. The conference ID is 32511819. Pleasedial in approximately 10 minutes prior to the start of the call.

To access the live webcast, go to the Investor Relations section of theCompany's website at http://www.iomai.com. Please connect to the web site atleast 15 minutes prior to the call to allow for any software download that maybe necessary. The webcast is also being distributed through the ThomsonStreetEvents Network. Individual investors can listen to the call athttp://www.earnings.com, Thomson's individual investor portal, powered byStreetEvents. Institutional investors can access the call via ThomsonStreetEvents (http://www.streetevents.com), a password-protected eventmanagement site.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune systemstimulants, delivered via a novel, needle-free technology calledtranscutaneous immunization (TCI). TCI taps into the unique benefits of amajor group of antigen-presenting cells found in the outer layers of the skin(Langerhans cells) to generate an enhanced immune response. Iomai isleveraging TCI to enhance the efficacy of existing vaccines, develop newvaccines that are viable only through transcutaneous administration and expandthe global vaccine market. Iomai currently has four product candidates indevelopment: three targeting influenza and pandemic flu and one to prevent E.coli-related travelers' diarrhea. For more information on Iomai, please visithttp://www.iomai.com.

Additional Information and Where to Find It

In connection with the proposed transaction, Iomai Corporation will befiling a proxy statement for its stockholders and other documents regardingthe proposed transaction with the Securities and Exchange Commission (SEC).BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, IOMAI STOCKHOLDERS ANDINVESTORS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT MATERIALSCAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THE DOCUMENTSWILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND IOMAI.Investors and stockholders may obtain copies of the proxy statement and otherrelevant documents filed with the SEC by Iomai free of charge at the SEC's website at http://www.sec.gov. In addition, investors and stockholders mayobtain copies of the proxy statement and other relevant documents filed withthe SEC by Iomai (when they are available) free of charge by going to Iomai'sInvestor Relations page on its corporate website at http://www.iomai.com.

Iomai and its directors, executive officers and other members ofmanagement may be deemed to be participants in the solicitation of proxiesfrom Iomai's stockholders with respect to the proposed transaction.Information regarding Iomai's executive officers and directors, and theirbeneficial ownership of Iomai's common stock as of March 26, 2008 is availablein Iomai's proxy statement for its 2008 Annual Meeting of Stockholders, whichwas filed with the SEC on April 4, 2008. Other information regarding theinterests of such potential participants in the proxy solicitation will becontained in the proxy statement and other relevant materials to be filed withth
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Iomai to Host Conference Call and Webcast Tomorrow...
S
Intercell AG to Acquire Iomai Corporation to Expan...